Scholars Central

Research articlePublished 12 Jan 2015

Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies

Authors: John M. Kane, Raymond Sanchez, Ross A. Baker, Anna Eramo, Timothy Peters-Strickl, Pamela P. Perry, Brian R. Johnson, Lan-Feng Tsai, William H. Carson, Robert D. McQuade W. Wolfgang Fleischhacker

Clinical Schizophrenia & Related Psychoses

Volume 9 · Issue 3 · Pages 79–87

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objectives: To further characterize the clinical profile of long-term treatment with aripiprazole once-monthly 400 mg (AOM 400) by examining patient-centered outcomes in adults with schizophrenia. Methods: Data are from 2 separate studies: a 52-week, multicenter, randomized, double-blind, placebo-controlled study and a 38-week, multicenter, randomized, double-blind, active-controlled study that evaluated the clinical profile of AOM 400 as maintenance treatment in patients with schizophrenia. The studies were conducted from July 2008 through February 2011 and from September 2008 through August 2012, respectively. Both studies included the Drug Attitude Inventory (DAI), the Medication Adherence Questionnaire (MAQ), the Patient Satisfaction with Medication Questionnaire, and a resource utilization and hospitalization form as prespecified patient-centered endpoints. Results: A total of 710 patients entered the oral stabilization phase in the 52-week study, and 403 patients were randomized to double-blind treatment. The corresponding sample sizes in the 38-week study were 842 and 662, respectively. In both studies, mean DAI and MAQ scores remained stable across all treatment phases; mean changes from baseline during the double-blind phase were not significantly different between treatment arms. Treatment satisfaction remained high throughout both studies, and most patients reported no or fewer side effects with AOM 400 relative to their prior medication. Most patients did not have unscheduled outpatient visits or hospitalizations throughout the studies. Conclusions: Data from 2 randomized, double-blind studies indicated that patient perceptions about treatment satisfaction, side effects, and medication adherence were maintained in patients with schizophrenia receiving maintenance treatment with AOM 400. Trial Registration: ClinicalTrials.gov: NCT00705783, NCT00706654.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Schizophrenia & Related Psychoses.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Schizophrenia & Related Psychoses
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “John M. Kane”
  • BylineArticles whose byline prints “Raymond Sanchez”
  • BylineArticles whose byline prints “Ross A. Baker”
  • BylineArticles whose byline prints “Anna Eramo”
  • BylineArticles whose byline prints “Timothy Peters-Strickl”
  • BylineArticles whose byline prints “Pamela P. Perry”
  • BylineArticles whose byline prints “Brian R. Johnson”
  • BylineArticles whose byline prints “Lan-Feng Tsai”